Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCPG1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for STELARA 90 mg/ml syringes. This firm fixed-price delivery order, issued on January 6, 2026, with an ultimate completion date of January 28, 2026, carries no set-aside designation, indicating the company competed on an unrestricted basis. The award is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense healthcare operations.
DMS Pharmaceutical Group operates as a critical regional prime vendor contractor under the PPV-G GEN V program, which was awarded to the company on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The company's established performance across numerous delivery orders demonstrates its capability to supply diverse pharmaceutical products, including specialty biologics such as STELARA (an immunosuppressant biologic), to military healthcare facilities worldwide. This delivery order represents routine pharmaceutical procurement activity within the broader framework of the company's prime vendor contract, supporting the Defense Logistics Agency's mission to ensure consistent and efficient medical supply chain operations for the Department of Defense.
Quick answers
Who was awarded contract SPE2DR26FCPG1?
SPE2DR26FCPG1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FCPG1 worth?
The government has obligated $16,584 on SPE2DR26FCPG1.
Is contract SPE2DR26FCPG1 an order under another contract?
Yes. SPE2DR26FCPG1 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPG1 competed?
The extent of competition for SPE2DR26FCPG1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award